JP2020526483A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526483A5 JP2020526483A5 JP2019570045A JP2019570045A JP2020526483A5 JP 2020526483 A5 JP2020526483 A5 JP 2020526483A5 JP 2019570045 A JP2019570045 A JP 2019570045A JP 2019570045 A JP2019570045 A JP 2019570045A JP 2020526483 A5 JP2020526483 A5 JP 2020526483A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- csa
- period
- dose
- plasma concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023040600A JP2023088944A (ja) | 2017-06-30 | 2023-03-15 | 心筋節活性化剤で心不全を治療する方法 |
| JP2025121073A JP2025165979A (ja) | 2017-06-30 | 2025-07-18 | 心筋節活性化剤で心不全を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527983P | 2017-06-30 | 2017-06-30 | |
| US62/527,983 | 2017-06-30 | ||
| PCT/US2018/040181 WO2019006235A1 (en) | 2017-06-30 | 2018-06-29 | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023040600A Division JP2023088944A (ja) | 2017-06-30 | 2023-03-15 | 心筋節活性化剤で心不全を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020526483A JP2020526483A (ja) | 2020-08-31 |
| JP2020526483A5 true JP2020526483A5 (enExample) | 2021-08-05 |
Family
ID=63013097
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570045A Pending JP2020526483A (ja) | 2017-06-30 | 2018-06-29 | 心筋節活性化剤で心不全を治療する方法 |
| JP2023040600A Pending JP2023088944A (ja) | 2017-06-30 | 2023-03-15 | 心筋節活性化剤で心不全を治療する方法 |
| JP2025121073A Pending JP2025165979A (ja) | 2017-06-30 | 2025-07-18 | 心筋節活性化剤で心不全を治療する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023040600A Pending JP2023088944A (ja) | 2017-06-30 | 2023-03-15 | 心筋節活性化剤で心不全を治療する方法 |
| JP2025121073A Pending JP2025165979A (ja) | 2017-06-30 | 2025-07-18 | 心筋節活性化剤で心不全を治療する方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11576910B2 (enExample) |
| EP (2) | EP4512470A3 (enExample) |
| JP (3) | JP2020526483A (enExample) |
| CN (1) | CN110996953A (enExample) |
| AU (2) | AU2018290983B2 (enExample) |
| BR (1) | BR112019028046A2 (enExample) |
| CA (1) | CA3068588A1 (enExample) |
| DK (1) | DK3645002T3 (enExample) |
| ES (1) | ES3008457T3 (enExample) |
| FI (1) | FI3645002T3 (enExample) |
| HR (1) | HRP20241729T1 (enExample) |
| HU (1) | HUE069805T2 (enExample) |
| LT (1) | LT3645002T (enExample) |
| MA (1) | MA49508B1 (enExample) |
| MD (1) | MD3645002T2 (enExample) |
| MX (2) | MX2020000190A (enExample) |
| PL (1) | PL3645002T3 (enExample) |
| PT (1) | PT3645002T (enExample) |
| RS (1) | RS66581B1 (enExample) |
| SI (1) | SI3645002T1 (enExample) |
| SM (1) | SMT202500067T1 (enExample) |
| WO (1) | WO2019006235A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20151786A1 (es) | 2013-03-14 | 2015-12-11 | Amgen Inc | Compuestos heterociclicos y sus usos |
| SG10202111790YA (en) | 2017-06-30 | 2021-12-30 | Amgen Inc | Synthesis of omecamtiv mecarbil |
| MA49508B1 (fr) * | 2017-06-30 | 2024-12-31 | Amgen Inc. | Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques |
| PL3594199T3 (pl) | 2018-07-09 | 2020-11-16 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania |
| MX2021001792A (es) | 2018-08-17 | 2021-05-27 | Amgen Inc | Sales y formas cristalinas de omecamtiv mecarbil. |
| BR112021023074A2 (pt) * | 2019-05-19 | 2022-03-29 | Myokardia Inc | Tratamento de disfunção sistólica e insuficiência cardíaca com fração de ejeção reduzida com o composto (r)-4-(l-(1-((3-(difluorometil)-l--1-metil-1h-pirazol-4-il)sulfonil)-l-1-fluoroetil)-n-(isoxazol-3-il)piperidina-l-1-carboxamida |
| JP7696353B2 (ja) * | 2020-02-10 | 2025-06-20 | アムジェン インコーポレイテッド | オメカムチブメカルビル製剤 |
| WO2021257456A1 (en) * | 2020-06-15 | 2021-12-23 | MyoKardia, Inc. | Treatment of atrial dysfunction |
| EP4243825B1 (en) | 2020-11-12 | 2025-11-12 | Amgen Inc. | Omecamtiv mecarbil for the treatment of heart failure in selected patient groups |
| CN116710139A (zh) * | 2020-11-12 | 2023-09-05 | 安进股份有限公司 | 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法 |
| TW202300479A (zh) | 2021-03-10 | 2023-01-01 | 美商安進公司 | 奧美卡替莫卡必爾之合成 |
| US20250161298A1 (en) * | 2022-02-22 | 2025-05-22 | Yale University | Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth |
| WO2024081611A1 (en) * | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| KR20250174911A (ko) | 2023-03-27 | 2025-12-15 | 엣지와이즈 테라퓨틱스, 인크. | 퀴놀리논 아미드 화합물 및 이의 용도 |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| CN1296417A (zh) | 1998-02-10 | 2001-05-23 | 卫福有限公司 | 控释制剂 |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| AU2003279842A1 (en) | 2002-10-04 | 2004-05-04 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| US7507735B2 (en) | 2004-06-17 | 2009-03-24 | Cytokinetics, Inc. | Compounds, compositions and methods |
| AR058347A1 (es) | 2005-12-15 | 2008-01-30 | Cytokinetics Inc | Entidades quimias composiciones y metodos |
| CA2651283A1 (en) | 2006-05-15 | 2007-11-22 | Wisconsin Alumni Research Foundation | Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin |
| FR2902092B1 (fr) | 2006-06-07 | 2008-09-05 | Sapelem Soc Par Actions Simpli | Appareil de manutention de charge |
| EP2139458A4 (en) | 2007-04-19 | 2013-01-23 | Dong A Pharm Co Ltd | COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA |
| AU2014240104B2 (en) * | 2013-03-14 | 2018-11-08 | Amgen Inc. | Heterocyclic compounds and their uses |
| PE20151786A1 (es) | 2013-03-14 | 2015-12-11 | Amgen Inc | Compuestos heterociclicos y sus usos |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| MX379899B (es) * | 2015-06-26 | 2025-03-11 | Cytokinetics Inc | Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal |
| AU2018214629A1 (en) | 2017-02-06 | 2019-08-22 | Acceleron Pharma Inc. | Compositions and methods for treating heart failure |
| MA49508B1 (fr) | 2017-06-30 | 2024-12-31 | Amgen Inc. | Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques |
| SG10202111790YA (en) | 2017-06-30 | 2021-12-30 | Amgen Inc | Synthesis of omecamtiv mecarbil |
| PL3594199T3 (pl) | 2018-07-09 | 2020-11-16 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania |
| EP3820851A1 (en) | 2018-07-12 | 2021-05-19 | Assia Chemical Industries Ltd | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| PL3599243T3 (pl) | 2018-07-26 | 2023-08-21 | Cvie Therapeutics Limited | Związki podobne do 17beta-heterocyklilu naparstnicy do leczenia niewydolności serca |
| MX2021001792A (es) | 2018-08-17 | 2021-05-27 | Amgen Inc | Sales y formas cristalinas de omecamtiv mecarbil. |
| US12442027B2 (en) | 2018-12-18 | 2025-10-14 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| BR112021017009A2 (pt) | 2019-03-05 | 2021-11-09 | Windtree Therapeutics Inc | Formulação intravenosa contendo istaroxima para o tratamento da insuficiência cardíaca aguda (ahf) |
| WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021053189A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| EP4041198A4 (en) | 2019-10-09 | 2023-08-16 | Dr. Reddy's Laboratories Limited | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF |
| US20220411374A1 (en) | 2019-10-09 | 2022-12-29 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| AU2020378197A1 (en) | 2019-11-10 | 2022-05-26 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| GB201918853D0 (en) | 2019-12-19 | 2020-02-05 | Lund Lars H | Methods of treatment |
| CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| JP7696353B2 (ja) | 2020-02-10 | 2025-06-20 | アムジェン インコーポレイテッド | オメカムチブメカルビル製剤 |
| EP4243825B1 (en) | 2020-11-12 | 2025-11-12 | Amgen Inc. | Omecamtiv mecarbil for the treatment of heart failure in selected patient groups |
| TW202300479A (zh) | 2021-03-10 | 2023-01-01 | 美商安進公司 | 奧美卡替莫卡必爾之合成 |
| WO2023205291A2 (en) | 2022-04-21 | 2023-10-26 | The Board Of Regents Of The University Of Oklahoma | Targeting myocardial tissue for delivery of therapeutic and imaging agents |
| WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| US11986474B1 (en) * | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
-
2018
- 2018-06-29 MA MA49508A patent/MA49508B1/fr unknown
- 2018-06-29 PT PT187457320T patent/PT3645002T/pt unknown
- 2018-06-29 MD MDE20200488T patent/MD3645002T2/ro unknown
- 2018-06-29 FI FIEP18745732.0T patent/FI3645002T3/fi active
- 2018-06-29 WO PCT/US2018/040181 patent/WO2019006235A1/en not_active Ceased
- 2018-06-29 LT LTEPPCT/US2018/040181T patent/LT3645002T/lt unknown
- 2018-06-29 PL PL18745732.0T patent/PL3645002T3/pl unknown
- 2018-06-29 BR BR112019028046-4A patent/BR112019028046A2/pt not_active Application Discontinuation
- 2018-06-29 RS RS20250023A patent/RS66581B1/sr unknown
- 2018-06-29 DK DK18745732.0T patent/DK3645002T3/da active
- 2018-06-29 ES ES18745732T patent/ES3008457T3/es active Active
- 2018-06-29 SM SM20250067T patent/SMT202500067T1/it unknown
- 2018-06-29 AU AU2018290983A patent/AU2018290983B2/en active Active
- 2018-06-29 EP EP24209435.7A patent/EP4512470A3/en active Pending
- 2018-06-29 JP JP2019570045A patent/JP2020526483A/ja active Pending
- 2018-06-29 SI SI201831198T patent/SI3645002T1/sl unknown
- 2018-06-29 EP EP18745732.0A patent/EP3645002B1/en active Active
- 2018-06-29 CA CA3068588A patent/CA3068588A1/en active Pending
- 2018-06-29 US US16/625,958 patent/US11576910B2/en active Active
- 2018-06-29 HR HRP20241729TT patent/HRP20241729T1/hr unknown
- 2018-06-29 MX MX2020000190A patent/MX2020000190A/es unknown
- 2018-06-29 HU HUE18745732A patent/HUE069805T2/hu unknown
- 2018-06-29 CN CN201880053343.0A patent/CN110996953A/zh active Pending
-
2020
- 2020-01-08 MX MX2022015115A patent/MX2022015115A/es unknown
-
2023
- 2023-01-17 US US18/155,483 patent/US12295952B2/en active Active
- 2023-03-15 JP JP2023040600A patent/JP2023088944A/ja active Pending
- 2023-05-05 US US18/313,267 patent/US11931358B2/en active Active
-
2024
- 2024-02-15 AU AU2024200991A patent/AU2024200991B2/en active Active
-
2025
- 2025-04-18 US US19/183,619 patent/US20250255862A1/en active Pending
- 2025-07-18 JP JP2025121073A patent/JP2025165979A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526483A5 (enExample) | ||
| JP2023088944A5 (enExample) | ||
| FI3645002T3 (fi) | Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla | |
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP2020529996A5 (enExample) | ||
| JP6309454B2 (ja) | 癌の併用処置 | |
| EA020193B1 (ru) | Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh) | |
| JP2015057436A5 (enExample) | ||
| JP2020502261A5 (enExample) | ||
| JP2019534304A5 (enExample) | ||
| JP2017513809A5 (enExample) | ||
| JP2017128610A (ja) | 併用ａｌｓ療法 | |
| Patel et al. | Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. | |
| WO2024081611A1 (en) | Methods for treating heart failure by administering cardiac sarcomere activators | |
| EP2303259A1 (en) | Dronedarone for the prevention of cardioversion | |
| WO2014176543A2 (en) | Methods of self-administration of vanoxerine for terminating acute episodes of cardiac arrhythmia in mammals | |
| WO2014134419A1 (en) | Use of ikach blockers for the treatment of cardiac diseases | |
| MX2022006404A (es) | Composicion farmaceutica para el tratamiento de la enfermedad vascular pulmonar y/o disfuncion cardiaca en pacientes paliados con fontan. | |
| WO2023025220A1 (zh) | 一种ARNi与钙离子拮抗剂的药物组合物与应用 | |
| JP2021091608A5 (enExample) | ||
| JP6028983B2 (ja) | ビダラビンによる心房細動治療 | |
| US20230201313A1 (en) | Methods of treating left ventricle hypertrophy | |
| US20160051542A1 (en) | Methods of administration of single doses of vanoxerine to terminate acute episodes of cardiac arrhythmia | |
| HK40125990A (zh) | 对心律无显着影响的库欣综合征的治疗 | |
| GONG et al. | Antihypertensive Effect of Tianmu Jiangya Powder on SHR Rats and Its Mechanism |